Sign Up to like & get
recommendations!
0
Published in 2017 at "Lung cancer"
DOI: 10.1016/j.lungcan.2016.11.001
Abstract: BACKGROUND Clinical guidelines highly recommended the detection of potentially targetable genetic aberrations such as anaplastic lymphoma kinase (ALK) rearrangements in patients with non-small cell lung cancer (NSCLC). Few methods, such as the ALK break apart…
read more here.
Keywords:
detection;
alk;
ihc fish;
russian patients ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2017 at "Translational cancer research"
DOI: 10.21037/12615
Abstract: The discovery of ALK rearrangements in non-small cell lung cancer (NSCLC) and their oncogenic properties by Soda et al . in 2007 gave the start to one of the most famous stories in the treatment…
read more here.
Keywords:
alk;
rearrangements created;
alk rearrangements;
cancer ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.863461
Abstract: Anaplastic lymphoma kinase (ALK) alterations in non-small cell lung cancer (NSCLC) can be effectively treated with a variety of ALK-targeted drugs. After the approval of the first-generation ALK inhibitor crizotinib which achieved better results in…
read more here.
Keywords:
alk inhibitors;
generation alk;
alk rearrangements;
targeting alk ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Journal of the National Comprehensive Cancer Network : JNCCN"
DOI: 10.6004/jnccn.2017.0058
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with a 5-year survival of 8%. Current therapeutic regimens are largely ineffective and underscore the need for novel treatment strategies. Chromosomal rearrangements involving the…
read more here.
Keywords:
ductal adenocarcinoma;
alk;
exon alk;
pancreatic ductal ... See more keywords